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Commentary
Bisphenol A (BPA), a component of poly-
carbonate plastics and epoxy resins, is one 
of the highest-volume chemicals produced 
worldwide. Many studies suggest that the 
amount of BPA to which humans are exposed 
may cause adverse health effects (reviewed by 
Bondesson et al. 2009).
The field of endocrine disruption, and 
particularly BPA research, has been influ-
enced by social issues, legislation, and the 
media. BPA has attracted the attention of 
regulatory agencies and scientists around the 
world because of its estrogenic properties 
(Wetherill et al. 2007). Since 2006, several 
panels and agencies have examined the BPA 
literature and have come to quite different 
conclusions regarding the safety of human 
exposure levels [reviewed by Gies et al. (2009) 
and Vandenberg et al. (2009)]. Specifically, 
exposure of humans to free (unconjugated) 
BPA has been questioned. These conflict-
ing decisions seem paradoxical because each 
was generated using approximately the same 
litera  ture database.
EFSA Risk Assessment: An 
Example of Use of Limited Data
As stated in our review (Vandenberg et al. 
2010), great concern exists about exposure 
of human fetuses, infants, and neonates to 
BPA because of the sensitivity of developing 
organs and the brain to exogenous hormones 
(Vandenberg et al. 2009). However, to trans-
late findings from animal studies to health 
risks in humans, exposure assessments and 
biomonitoring of BPA in different popu-
lations are essential. Thus, in November 2006, 
the European Food Safety Authority (EFSA) 
released its opinion on the plausibility of data 
regarding levels of BPA in human blood and 
excretion of BPA and BPA metabo  lites in 
environmentally exposed humans. The EFSA 
panel (2006) concluded that 
[T]here is very low oral bioavailability of the parent 
substance, BPA, in humans and other primates. 
Due to this rapid biotransformation and excre-
tion and plasma protein binding in humans, peak 
BPA-concentrations after dietary exposures to BPA 
available for receptor binding are predicted to be 
very low even in worst case exposure scenarios.
The EFSA panel was asked to reconsider 
their assessment based on recent studies that 
suggested the possibility for age-dependent 
toxico  kinetics of BPA. In July 2008, the 
EFSA released its second opinion in support 
of their original statement (EFSA 2008): 
The Panel therefore considers that its previous risk 
assessment … can be considered as conservative 
for humans. The Panel concluded that the differ-
ences in age-dependent toxicokinetics of BPA in 
animals and humans would have no implication 
for the EFSA 2006 risk assessment of BPA.
In stark contrast to these statements, we 
analyzed > 80 biomonitoring studies and 
came to the conclusion that measurable levels 
of BPA and BPA conjugates are present in 
human blood and urine, as well as in other 
tissues and fluids (Vandenberg et al. 2010). 
These biomonitoring studies examined thou-
sands of individuals from many developed and 
some developing countries and collectively 
indicate that humans are internally exposed to 
unconjugated BPA (Vandenberg et al. 2007, 
2010; Welshons et al. 2006). Biomonitoring 
studies are crucial for understanding current 
human exposure levels because, by their very 
nature, they account for all exposures. This is 
essential, because all exposure sources for BPA 
have not yet been identified, and existing data 
suggest that non-oral exposures may be signifi-
cant (Gies et al. 2009; Stahlhut et al. 2009).
A comprehensive review of the large num-
ber of biomonitoring studies indicates that 
they are highly consistent and therefore reli-
able (Vandenberg et al. 2010). The detection 
rates and concentrations of BPA in urine and 
blood of environmentally exposed individuals 
are remarkably similar in studies performed 
in many laboratories using a variety of tech-
niques, including highly accurate and sensitive 
methods [e.g., solid-phase extraction coupled 
with isotope dilution-HPLC-tandem mass 
spectrometry, as used by the U.S. Centers for 
Disease Control and Prevention (Calafat et al. 
2005, 2008)]. Further, there is no evidence to 
suggest that these studies should be invalidated 
because of poor quality control (e.g., contami-
nation from collection materials, break  down 
of conjugates during storage, inadequate   
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Ba c k g r o u n d: Within the past 3 years, four major evaluations of bisphenol A (BPA) safety have 
been undertaken. However, these assessments have arrived at quite different conclusions regarding 
the safety of BPA at current human exposure levels.
oBjectives: We compared the reasons provided by the European Food Safety Authority (EFSA) BPA 
risk assessment panel for their conclusion that human exposures are negligible with the conclusions 
reached by the other panels, with all panels having the same body of literature at their disposal.
discussion: The EFSA panel dismissed ≥ 80 biomonitoring studies that documented significant 
levels of BPA exposure in humans, including internal exposures to unconjugated BPA, on the basis 
that they did not match a model of BPA metabolism. Instead, the EFSA panel relied on two toxico-
kinetic studies—conducted in 15 adults administered BPA—to draw conclusions about exposure 
levels in the population, including exposures of neonates.
co n c l u s i o n s: As with all exposure assessments, models should be developed to explain actual data that 
are collected. In the case of BPA, samples from a large number of human subjects clearly indicate that 
humans are internally exposed to unconjugated BPA. The dismissal of these biomonitoring studies sim-
ply because their results do not conform to a model violates scientific principles. Expert panels should 
evaluate all data—including human biomonitoring studies—to make informed risk assessments.
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blanks) (Gies et al. 2009; Vandenberg et al. 
2010). In total, the reproducibility of these 
results indicates that humans are internally 
exposed to doses of unconjugated BPA, with 
a central measure of the distribution in the 
0.5–3 ng/mL range. In spite of these con-
sistent findings, the EFSA panel came to a 
completely different conclusion about current 
human exposures (EFSA 2006, 2008). What 
is the basis for this disparity?
The pivotal factor we identified in the 
EFSA report was the bias in the selection of 
studies used in this evaluation. The EFSA 
panel (EFSA 2006) ignored the majority of the 
biomonitoring studies. Although they reviewed 
2 toxico  kinetic studies (Volkel et al. 2002, 
2005) extensively, only 2 of the 17 urine bio-
monitoring studies published by 2006 were 
discussed in any detail. Only a small number 
of the blood biomonitoring studies were cited 
in the EFSA report, and none of these studies 
were discussed in detail at any level. Instead, 
the EFSA panel identified potential problems 
with these biomonitoring studies, including 
the use of ELISA (used only in a few studies), 
possible contamination of reagents with BPA, 
and the leaching of BPA from materials used 
for sample collection, storage, and processing. 
Without providing any evidence that these 
are indeed issues in the biomonitoring studies 
examined, the EFSA (2006) concluded that 
Due to all these confounders, the reported   analytical 
results on BPA blood concentrations most probably 
considerably overestimate real blood concentrations 
actually present.
Of particular concern relative to this stance 
is that although the biomonitoring studies have 
produced reliable, consistent results, the two 
toxicokinetic studies (Volkel et al. 2002, 2005) 
the EFSA (2006) relied upon heavily for their 
risk assessment have significant inconsistencies 
and are yet to be replicated. Most concerning 
is the fact that the methods used in these two 
toxico  kinetic studies were much less sensitive 
than those used in almost all bio  monitoring 
studies. The toxico  kinetic studies had limits 
of detection (LODs) as high as 2.28 ng/mL   
for unconjugated BPA and 10.1 ng/mL for 
conjugated BPA, compared with LODs of 
0.0063–0.4 ng/mL in other studies using 
similar analytical methods (Vandenberg et al. 
2010). These two toxicokinetic studies exam-
ined only a small number of adult subjects 
adminis  tered BPA (15 adults total) compared 
with the thousands of individuals (including 
infants, children, adolescents, and pregnant 
women) sampled for biomonitoring purposes. 
Only one of these studies (Volkel et al. 2002) 
examined concentrations of BPA in both 
blood and urine samples, whereas the other 
study (Volkel et al. 2005) reported conjugated 
BPA concentrations in urine but provided no 
information about BPA concentrations in the 
plasma samples collected by the authors. Yet 
both studies were used by the EFSA to dis-
count the presence of BPA in plasma and blood 
samples reported in numerous other studies 
(EFSA 2006). Additional problems with data 
analysis and interpretation in the Volkel et al. 
studies (2002, 2005) are discussed in greater 
detail in our review (Vandenberg et al. 2010).
The EFSA panel (2006) speculated that 
the repeated detection of unconjugated BPA 
in human blood was due to poor sample pro-
cessing conditions and/or unreliable methods, 
stating, 
The studies reporting detection of BPA in human 
blood in concentrations higher than 1 [µg] 
BPA/L have usually determined [unconjugated] 
BPA, without prior enzymatic cleavage of BPA-
glucuronide.… The fate of BPA-glucuronide 
under the conditions of the diverse sample pro-
cessing conditions and a possible cross-reactivity of 
the [ELISA] antibodies with BPA-glucuronide is 
not reported, leaving the possibility that reported 
BPA levels actually reflect BPA-glucuronide levels.
Consistent results from a large number of 
biomonitoring studies cannot be dis  regarded 
based only on the speculation that they over-
estimated unconjugated BPA levels because of 
hypothetical poor analytical controls. The defi-
ciencies speculated by the EFSA were addressed 
and invalidated by one or more appropriate 
controls within each of the individual biomoni-
toring studies in question; most studies 
contained numerous controls to counter specu-
lations of contamination or cross-reactivity of 
ELISA anti  bodies. For example, blanks reported 
in these studies would show measurable BPA if 
cross-contamination occurred at any step in the 
sample-handling process or analysis—yet they 
did not, leaving the speculations made by the 
EFSA without any scientific basis.
The EFSA panel (EFSA 2006) continued 
to rationalize their dismissal or lack of atten-
tion to bio  monitoring studies by referencing 
the results of toxico  kinetic studies: 
[O]rally administered BPA is rapidly absorbed 
from the gastrointestinal tract and undergoes 
intensive first-pass metabolism to BPA-glucuronide 
in the gut wall and in the liver.… Concentrations 
of [unconjugated] BPA were below the limit of 
detection both in urine … and blood samples…. 
Further reasoning provided to reject the find-
ings from biomonitoring studies was that the 
levels measured in environmentally exposed 
humans are “higher than the peak BPA concen-
trations determined in blood of monkeys after 
oral administration of a dose of 100 µg BPA/kg 
bw [body weight].” The panel concluded that 
[T]hese reported concentrations of BPA in blood 
of unintentionally exposed human subjects of up to 
10 [µg] BPA/L are orders of magnitude above the 
maximal concentrations of BPA predicted in blood 
by PBPK [physiologically-based pharmaco  kinetic] 
models on the basis of human BPA toxico  kinetics 
after oral administration.
In science, if data contradict the hypothe-
sis (i.e., the model), the hypothesis, not the 
data, must be rejected. It is unexpected, and 
perhaps unprecedented, for a scientific body 
to reject studies because their findings did 
not match a model, rather than to reconsider 
the model or reassess the findings from the 
extremely limited toxico  kinetic studies that 
were used to generate the model. This rea-
soning is simply not founded in logic and is 
not how science-based regulatory decisions 
should be made. Considering the size of the 
biomonitoring literature, the consistency 
of the results from biomonitoring studies, 
and the significant problems in the toxico-
kinetic studies, conclusions drawn primarily 
from the two toxico  kinetic studies (Volkel 
et al. 2002, 2005) cannot be valid. Therefore 
the EFSA conclusion that there is negligible 
internal exposure to unconjugated BPA has 
no scientific basis.
The EFSA Panel Inappropriately 
Extrapolates from Adults to 
Fetuses and Neonates
Considering the reliance of the EFSA panel 
on two extremely limited toxico  kinetic studies 
to inform their risk assessment, their state-
ment that “the differences in age-dependent 
toxicokinetics of BPA in animals and humans 
would have no implication for the EFSA 
2006 risk assessment of BPA” (EFSA 2008) 
is particularly surprising. The July 2008 EFSA 
report stated, 
The Panel considers that there is sufficient capacity 
in the neonate to conjugate BPA at doses below 
1 mg/kg bw (the Panel noted that exposures at 
the TDI of 0.05 mg/kg bw are 20 fold lower than 
this). Therefore, the Panel concluded that there is 
sufficient capacity for biotransformation of BPA 
to hormonally inactive conjugates in neonatal 
humans at exposures to BPA that were considered 
in the EFSA opinion of 2006 and the European 
Union Risk Assessment Report. 
To date, there are no studies to support 
this statement. To the contrary, there are 
many studies that contradict it. First, the 
two toxico  kinetic studies relied upon by 
EFSA (Volkel et al. 2002, 2005) examined 
a total of 15 adults (mixed groups of males 
and females) adminis  tered BPA. Although 
the authors of these studies concluded that 
there are no kinetic differences between 
volun  teers (Volkel et al. 2005), evaluation of 
the data presented shows variable metabolic 
responses after BPA adminis  tration. Second, 
data from bio  monitoring studies in different 
groups of adults clearly indicated differences 
in urinary concentrations of BPA that are 
influenced by both sex and age (Calafat et al. 
2005, 2008; He et al. 2009). Associations 
between age and BPA concentrations are also 
evident from studies that examined children 
and adolescents; younger children typically BPA risk assessments need biomonitoring studies
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have higher concentrations of BPA metabo-
lites in urine compared with older children 
and adolescents (Becker et al. 2009; Calafat 
et al. 2008). Infants in a neonatal infant 
care unit were found to have total urinary 
BPA concentrations approximately 11 times 
higher than those observed in adults (Calafat 
et al. 2009). Third, researchers using two 
physiologically based toxico  kinetic models 
that simulated the blood concentration time 
profile in several age groups predicted that 
newborns have 3–11 times greater blood 
BPA concentrations than adults (Edginton 
and Ritter 2009; Mielke and Gundert-Remy 
2009). Finally, a recently published study 
examining rat fetuses provides evidence that 
BPA-glucuronide passes from the mother 
through the placenta and is deconjugated to 
BPA in the fetus, clearly showing that BPA 
metabolites can be converted to the biologi-
cally active form in the fetus (Nishikawa 
et al. 2010). A study of human placentas also 
indicates that unconjugated BPA crossing 
the placental barrier remains largely in its 
unconjugated form. Less than 4% of BPA 
detected in the fetal compartment was conju-
gated (Balakrishnan et al. 2010).
Similarly, there is little evidence in sup-
port of complete conjugation of BPA, even in 
adults. Six of the seven biomonitoring studies 
testing for unconjugated BPA in urine found 
measurable concentrations in at least some 
individuals examined (Calafat et al. 2009; 
Kim et al. 2003; Ouichi and Watanabe 2002; 
Schoringhumer and Cichna-Markl 2007; 
Volkel et al. 2008; Ye et al. 2005). The one 
study that failed to detect unconjugated BPA 
examined five pooled urine samples (Brock 
et al. 2001). One of the toxicokinetic studies 
relied heavily upon by the EFSA (2006, 2008) 
also detected unconjugated BPA in the urine 
of two of the six individuals administered 
BPA (Volkel et al. 2005). The presence of 
unconjugated BPA in urine suggests that first-
pass metabolism of orally administered BPA 
may be incomplete, that significant levels of 
BPA enter the body via routes that circumvent 
first-pass metabolism, or that BPA metabolites 
are deconjugated in the body. Importantly, 
unconjugated BPA has also been measured 
in fetal umbilical cord blood, amniotic fluid, 
and placental tissue (Vandenberg et al. 2010). 
Collectively, these findings clearly indicate 
that the fetus does not have “sufficient capac-
ity for biotransformation of BPA to hormon-
ally inactive conjugates” (EFSA 2008) and 
that human adults may not either.
Divergent Conclusions from 
Other Expert Panels
In the past few years, three other major evalu-
ations of the BPA toxicological database have 
been undertaken. These expert panels came 
to seemingly disparate conclusions, yet all 
four evaluations took place within a short 
period of time and had access to essentially 
the same literature. How is it possible for the 
same studies to be reviewed so differently by 
regulatory agencies [the EFSA and the U.S. 
Food and Drug Administration (FDA)], the 
National Toxicology Program (NTP), and 
academic scientists?
The answer lies in how the various panels 
evaluated the scientific litera  ture. In a pre-
vious commentary in Environmental Health 
Perspectives, Myers et al. (2009) described the 
selection process used by each panel in its 
assessment of the hundreds of animal studies 
that, to date, overwhelmingly indicate that 
developmental exposure to BPA causes adverse 
effects. The EFSA (2006) and FDA (2008) 
assessments used only data produced using 
vali  dated protocols [i.e., studies that con-
formed to Good Laboratory Practices (GLP)] 
with the ability to establish no observed 
adverse effect levels. Although the EFSA and 
FDA stated that they would use all available 
data to make regulatory decisions, their guide-
lines restricted their focus to only a few GLP-
compliant studies; all other studies (nearly 
1,000 for BPA) were not used because they 
did not meet this criterion.
Similarly, the EFSA panel (EFSA 2006) 
clearly divided the human exposure data-
base into two groups: dozens of biomonitor-
ing studies (which did not fit their model of 
BPA metabo  lism and were largely ignored or 
rejected) and two toxico  kinetic studies (which 
fit their model and were used in spite of their 
higher LODs and small number of individuals 
examined). The studies used by the other three 
expert panels and the conclusions reached by 
each of these panels are discussed below.
Chapel Hill Consensus 
Statement
In the fall of 2007, a group of scientists from 
universities and government agencies devel-
oped a workshop sponsored by the National 
Institutes of Health to which experts research-
ing BPA and other endocrine-disrupting 
chemi  cals were invited. These academic sci-
entists wrote the Chapel Hill Consensus 
Statement (vom Saal et al. 2007), which stated, 
in part, that “the commonly reported circulat-
ing levels in humans exceed the circulating 
levels extrapolated from acute exposure studies 
in laboratory animals.”
In reaching these conclusions, vom Saal 
et al. (2007) examined the entire body of 
scientific data (Crain et al. 2007; Keri et al. 
2007; Richter et al. 2007; Vandenberg et al. 
2007; Wetherill et al. 2007), including 
> 40 human biomonitoring studies available 
at the time and the two human toxico  kinetic 
studies. The panel concluded that humans, 
including children, adult men and women, 
and pregnant women, have meas  urable 
levels of unconjugated BPA in their bod-
ies, stating succinctly that “[h]uman expo-
sure to BPA is widespread” (vom Saal et al. 
2007). Additionally, a subpanel of experts 
(Vandenberg et al. 2007) concluded that
Unconjugated BPA has been measured repeatedly 
in human blood (serum and plasma) with a central 
measure of the distribution in the 0.3–4.4 ng/ml 
range (1–19.4 nM), and in breast milk, amniotic 
fluid, and placental tissue in the low [nanograms 
per milliliter] or [nanograms per gram] range. 
NTP
During the same period of time, the NTP 
Center for the Evaluation of Risks to Human 
Reproduction (CERHR) established a com-
mittee to evaluate the effects of BPA on repro-
ductive health in humans (CERHR 2007). The 
original CERHR report, and several sub  sequent 
drafts, were challenged and harshly criticized 
by scientists because they used arbitrary cri-
teria to evaluate animal studies, applied these 
criteria unevenly to different studies, and con-
tained scientific errors and mis  interpretations 
of published data [reviewed by Vandenberg 
et al. (2009)]. In the spring of 2008, the NTP 
undertook its own extensive review of the BPA 
literature, including recom  mendations from 
the CERHR report and comments from the 
public (NTP 2008).
The NTP (2008) limited its review 
to those studies related to risks for human 
reproduction; most of the human exposure 
studies available at the time were included 
in the assessment, whereas only a portion of 
the animal literature was considered useful. 
Regarding human exposures, the NTP came 
to a much less decisive conclusion compared 
with the Chapel Hill panel (vom Saal et al. 
2007), stating that “there are data reporting 
bisphenol A concentrations in urine, breast 
milk, and amniotic fluid.” Yet, the NTP 
(2008) also stated that the many biomonitor-
ing studies may be unreliable because BPA 
conjugates can be unstable under some storage 
conditions and because laboratory equipment 
may leach BPA: “it is possible that free bisphe-
nol A concentrations measured in biological 
samples may be over  estimated.” Similar to the 
EFSA report (EFSA 2006), the NTP (2008) 
reached these conclusions without evidence 
that contaminations had occurred.
FDA
The FDA assessed the BPA literature in 2008 
(FDA 2008), stating in their assessment   
summary that 
Based on our ongoing review, we believe there is 
a large body of evidence that indicates that FDA-
regulated products containing BPA currently on 
the market are safe and the exposure levels to BPA 
from food contact materials, including for infants 
and children, are below those that may cause 
health effects.Vandenberg et al.
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The FDA (2008) largely avoided the issue 
of current human exposure levels, giving very 
little attention to either the available (> 40) 
biomonitoring studies or the toxicokinetic 
studies. The FDA (2008) summarized that 
There are several publications detailing meas  ure-
ments in biological fluid for BPA. Although [the] 
FDA is aware of these data and considers them 
extremely useful, [the] FDA also understands the 
experimental limitations that have been identified 
with regard to these data.... [The] FDA’s updated 
safety assessment is focused on a subpopulation, 
infants. Accordingly, the currently available data, 
which consider exposure to adults or young chil-
dren (6 years of age or older), were not used or 
relied upon in FDA’s safety assessment.
Thus, to make their decision, the FDA included 
no bio  monitoring studies, even those from 
adults that clearly indicate internal exposures to 
unconjugated BPA (Vandenberg et al. 2010).
Biomonitoring Studies Should 
Be Used to Generate Risk 
Assessments
In our opinion, it is time to reassess how 
regu  la  tory agencies such as the EFSA make 
decisions. Agencies should consider all avail-
able data in making risk assessments. As pre-
viously argued by Myers et al. (2009), the 
value of the peer-reviewed literature should 
not be judged on its ability to meet stringent 
regulatory criteria but on the strength of the 
integrated data. The large database of human 
biomonitoring data should be used to define 
human exposure levels and develop models 
for risk assessment. Studies in which humans 
were environmentally exposed to BPA are 
particularly relevant in this regard for assess-
ing true human exposure levels, especially 
because BPA metabolism is influenced by age, 
sex, and physiological state (pregnant vs. non-
pregnant) (Calafat et al. 2009; Vandenberg 
et al. 2007; Zalko et al. 2003). In addition, 
the two available toxico  kinetic studies should 
be evaluated in their correct context, consid-
ering that a) their findings do not match find-
ings from a large number of biomonitoring 
studies; b) there are serious inconsistencies in 
their methods and reported results; c) these 
studies are yet to be replicated; and d) these 
studies provide no information about fetal or 
neonatal exposure to BPA.
In summary, there is still significant con-
troversy surrounding current human exposures 
to BPA. We propose that this controversy is 
not due to the lack of valid scientific bio  moni-
toring studies, but instead stems from risk 
assessments generated using the same literature 
but applying different selection criteria that 
are not scientifically valid. We hope that the 
BPA saga will stimulate regulatory agencies to 
reassess how they determine the usefulness of 
the peer-reviewed literature and lead to the use 
of one integrated database of scientific infor-
mation, including biomonitoring studies, to 
protect human health.
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